Detalles de la búsqueda
1.
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
World J Urol
; 41(12): 3485-3491, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37921936
2.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 23(10): 1308-1320, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36113498
3.
Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
J Urol
; 204(5): 934-940, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32330406
4.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol
; 20(11): 1531-1543, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31540791
5.
Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
J Urol
; 201(6): 1121-1126, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30835607
6.
Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
J Urol
; 201(4): 721-727, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30664083
7.
Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
Curr Oncol Rep
; 21(5): 43, 2019 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30919165
8.
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
J Urol
; 200(2): 335-343, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29534997
9.
Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
J Urol
; 199(6): 1475-1481, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29246734
10.
Correction to: RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy.
Int J Behav Nutr Phys Act
; 15(1): 124, 2018 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514302
11.
RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy.
Int J Behav Nutr Phys Act
; 15(1): 49, 2018 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880049
12.
Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).
J Cancer Educ
; 33(3): 551-556, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27526692
13.
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Lancet Oncol
; 18(9): 1192-1201, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28760403
14.
Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
J Urol
; 197(2): 335-341, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27545574
15.
Improving prostate cancer care collaboratively - a multidisciplinary, formal, consensus-based approach.
Can J Urol
; 24(1): 8646-8650, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28263130
16.
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Lancet Oncol
; 17(6): 727-737, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155740
17.
Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
J Urol
; 195(5): 1409-1414, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26707510
18.
Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
J Urol
; 196(6): 1651-1658, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27569437
19.
Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.
J Urol
; 194(1): 79-84, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25660208
20.
A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance.
J Magn Reson Imaging
; 41(1): 220-5, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25044935